Thurston, Springer, Miller, Herd & Titak, Inc. Vertex Pharmaceuticals Inc Transaction History
Thurston, Springer, Miller, Herd & Titak, Inc.
- $475 Million
- Q4 2024
A detailed history of Thurston, Springer, Miller, Herd & Titak, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Thurston, Springer, Miller, Herd & Titak, Inc. holds 1,769 shares of VRTX stock, worth $817,472. This represents 0.15% of its overall portfolio holdings.
Number of Shares
1,769
Previous 1,096
61.41%
Holding current value
$817,472
Previous $509,000
39.88%
% of portfolio
0.15%
Previous 0.15%
Shares
3 transactions
Others Institutions Holding VRTX
# of Institutions
1,751Shares Held
227MCall Options Held
1.63MPut Options Held
1.47M-
Capital World Investors Los Angeles, CA28.3MShares$13.1 Billion1.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.3MShares$10.7 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$9.85 Billion0.23% of portfolio
-
State Street Corp Boston, MA12MShares$5.54 Billion0.2% of portfolio
-
Capital Research Global Investors Los Angeles, CA10.4MShares$4.82 Billion0.9% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $119B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...